SMAD4 and breast carcinoma: Reports on miR-19b-3p demonstrated that it inhibits cell proliferation in breast cancer via the PI3K/Akt pathway (11), whereas, by contrast, it promotes cell proliferation in colon cancer via targeting SMAD4 (12).